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1. Abstracts in English and Greek 
1.1 Abstract in English  
 Objective/Design: Gestational diabetes mellitus (GDM) has been associated with serious 
complications for both the pregnant woman and the newborn. Vitamin B12 is implicated in some important 
metabolic procedures such as methylation and one carbon cycle and its deficiency can cause serious health 
problems, such as hyperhomocysteinemia, defective synthesis of neurotransmitters and fatty acids and more. 
However, it is not known if there is a link between vitamin B12 deficiency and the risk of GDM. The 
purpose of this study is to systematically investigate and meta-analyze the evidence that exists up to date 
for this association.  
Methods: A comprehensive research was conducted in PubMed, Scopus and Cochrane Central 
Register of Controlled Trials up to November 30th, 2018. Data are expressed as odds ratio (OR) with 95% 
confidence intervals (CI). The I2 index was employed for heterogeneity.  
            Results: Six studies (n=1,810 pregnant women, 309 GDM cases) fulfilled eligibility criteria for 
qualitative and two studies for quantitative analysis. Women with vitamin B12 deficiency were at higher 
risk for developing GDM when compared with those who were vitamin B12 sufficient: OR 1.81 (95% CI, 
1.25-2.63, I2: 0%). Due to the small number of studies, the role of potential confounders could not be clearly 
estimated.  
          Conclusions: Vitamin B12 deficiency seems to be associated with increased risk of GDM. The 
pathogenetic mechanisms for this association need to be clarified in future studies. 
          
        Keywords: vitamin B12, gestational diabetes mellitus, pregnancy, diabetes, vitamin B12 deficiency  
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1.2 Abstract in Greek 
 
             Αντικείμενο/Σχεδιασμός έρευνας: Ο σακχαρώδης διαβήτης κύησης (GDM), έχει συνδεθεί με 
σοβαρές επιπλοκές τόσο για τη γυναίκα που κυοφορεί, όσο και για το νεογνό. Η βιταμίνη Β12 εμπλέκεται 
σε σημαντικές μεταβολικές διεργασίες όπως η μεθυλίωση και ο κύκλος του φυλλικού οξέως και η έλλειψή 
της μπορεί να προκαλέσει σοβαρά προβλήματα υγείας, όπως υπερομοκυστεϊναιμία., ελαττωματική 
σύνθεση νευροδιαβιβαστών και λιπαρών οξέων και άλλα. Ωστόσο, δεν είναι γνωστό αν υπάρχει κάποια 
σύνδεση μεταξύ της έλλειψης βιταμίνης Β12 και του σακχαρώδη διαβήτη κύησης. Ο σκοπός αυτής της 
μελέτης είναι να γίνει συστηματική ανασκόπηση και μετα-ανάλυση των δεδομένων που υπάρχουν μέχρι 
σήμερα για τη πιθανή συσχέτιση των δύο παραγόντων.  
 Μέθοδος: Η έρευνα πραγματοποιήθηκε μέσα από τις βάσεις δεδομένων PubMed, Scopus, Cochrane 
Central Register Of Controlled Trials μέχρι και τις 30 Νοεμβρίου 2018. Τα δεδομένα παρουσιάστηκαν ως 
αναλογία πιθανοτήτων (OR) και 95% διάστημα εμπιστοσύνης (95% CI). Ο δείκτης I2 χρησιμοποιήθηκε για 
την ετερογένεια των αποτελεσμάτων.  
 Αποτελέσματα: Έξι μελέτες συμπεριλήφθηκαν στη συστηματική ανασκόπηση και δύο μελέτες από 
αυτές παρείχαν τα απαραίτητα δεδομένα ώστε να μετά-αναλυθούν. Συνολικά, 1810 έγκυες γυναίκες 
μελετήθηκαν, με 309 περιπτώσεις διαβήτη κύησης. Οι γυναίκες με ανεπάρκεια βιταμίνης Β12 είχαν 
μεγαλύτερο ρίσκο εμφάνισης διαβήτη κύησης: OR 1,81 (95% CI 1.25-2.63), Heterogeneity (I2) 0%. 
Εξαιτίας του μικρού αριθμού των μελετών που υπάρχουν μέχρι σήμερα, ο ρόλος των παραγόντων που θα 
μπορούσαν να επηρεάσουν τη συσχέτιση  δεν μπόρεσε να εκτιμηθεί επακριβώς.  
 Συμπέρασμα: Η ανεπάρκεια της βιταμίνης Β12 φαίνεται να σχετίζεται με αυξημένο κίνδυνο 
σακχαρώδη διαβήτη κύησης. Οι παθογενετικοί μηχανισμοί για αυτή τη συσχέτιση θα πρέπει να 
διευκρινιστούν σε μελλοντικές μελέτες.  
 
 Λέξεις κλειδιά: βιταμίνη Β12, διαβήτης κύησης, εγκυμοσύνη, διαβήτης, ανεπάρκεια βιταμίνης Β12  
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2. Introduction 
 The term ¨diabetes mellitus¨ (DM), describes a multifactorial disorder of carbohydrate, fat and 
protein metabolism, resulting from a defect in  insulin secretion, action or both, with subsequent long-term 
health consequences, due to multi-organ failure (1).  The term ¨gestational diabetes mellitus¨ (GDM), 
describes a state of carbohydrate intolerance of variable severity with onset of recognition during pregnancy. 
The definition is applied whether insulin or diet modification is used for treatment and whether this 
condition persists after pregnancy (2).  
 Therefore, women who become pregnant and who are known to have DM which antedates 
pregnancy do not have GDM, but ‘DM and pregnancy’ and should be treated accordingly before, during 
and after pregnancy (1). 
 GDM is a topic of major interest for many reasons. First it is a very common condition affecting up 
to 16% of women in high-risk populations (3). Second, it can lead to adverse pregnancy outcomes, as it 
affects both mother and fetus. Third,  appropriate treatment may improve maternal health and quality of life 
and can also diminish the perinatal morbidity/mortality (4). 
 Diabetogenic effect of pregnancy is thought to play an important role in the development of GDM, 
where human placental lactogenic hormone (HPL) secreted from placenta during pregnancy results in 
insulin desensitization, leading to physiological increases in blood glucose levels, particularly during the 
last two trimesters of pregnancy (5). 
   The increase in growth hormone, cortisone, estrogen and progesterone concentrations during 
pregnancy also contribute in insulin resistance (6, 7). Furthermore, maternal age, ethnicity, genetics, 
polycystic ovary syndrome, hypertension and obesity are associated with higher risk of GDM (8, 9). 
 Over the last 20 years, the rates of obesity have doubled and this can be measured by the rise in the 
body mass index (BMI) in the general population which is doubling (7.6% to 15.6%) and the proportion of 
obese women at the time of conception which is also increasing (10). These rising rates  of adiposity have 
led  researchers to investigate if the paradox of  nutritional deficiencies in those who are overweight or 
obese, may have implications in maternal health and the development of the embryo as a potential 
consequence of this phenomenon (11). 
 The micronutrients vitamin B12 and folate are necessary in order to support the increased demands 
of the fetus during pregnancy. Both vitamins are involved in metabolic processes such as the methylation 
process, the one carbon metabolism as well as epigenetic processes and DNA repair. Deficiency of these 
essential vitamins lead to megaloblastic anemia, growth retardation in utero, birth defects and 
neurocognitive disorders in the off-spring (12).  
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          The primary aim of this systematic review was to investigate the relation between B12 deficiency 
during pregnancy and the risk of GDM. Secondary aim was the effect of BMI and other factors on this 
association.   
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3. General part 
3.1 Gestational diabetes mellitus (GDM) 
3.1.1 Classification 
 According to the World Health Organization (WHO), DM is classified into four categories: type 1 
DM (T1DM), type 2 DM (T2DM), other rare types of DM and GDM. T1DM is characterized by 
autoimmune destruction of β-cells of the pancreas, which has been linked to genetic susceptibility, a 
diabetogenic trigger and/or exposure to a driving antigen (13). T2DM is characterized by insulin resistance 
and insulin deficiency. As far as the rare types of DM are concerned, they include the genetic defects of β-
cell function or insulin action, diseases of the exocrine pancreas and drug-induced DM. GDM is considered 
as a fourth type, characterized by glucose intolerance that appears or is recognized for the first time during 
pregnancy (14, 15). 
 
3.1.2 Pathophysiology 
 Adaptation of the maternal metabolism during pregnancy involves a number of physiological 
changes such as a greater fall in plasma glucose and amino acids and a greater rise in free fatty acids after 
an overnight fasting compared with the non-pregnant state (‘accelerated starvation’), which are associated 
with insulin resistance. In later pregnancy, a progressive rise in postprandial glucose and its associated 
insulin response, associated with decreased insulin sensitivity, parallels the growth of the fetal placental unit 
and rapidly reverses after delivery (16). GDM shares many pathophysiological characteristics with T2DM, 
most importantly insulin resistance (16).  
          The following figure shows the association between GDM and T2DM. The horizontal axis represents 
time and the vertical axis represents insulin production and/or action. The green line represents a woman 
who will never develop either GDM or T2DM (“control”). Although the production and action of insulin 
declines with age, she always remains above the threshold of developing clinical DM. During pregnancy, 
this woman develops insulin resistance, mainly due to the placental hormone production which antagonizes 
insulin. Nevertheless, she will not develop GDM, as the pancreas has functional reserves and is capable of 
producing larger amounts of insulin. Normally, after delivery, insulin production and action return to the 
pre-pregnancy levels. On the other hand, the red line represents a woman who will develop GDM, and 
possibly T2DM (“patient”). She is probably genetically predisposed to T2DM and/or has adopted a 
suboptimal lifestyle (e.g. obesity, lack of exercise). Although her insulin action is already at the lower level 
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compared with the control, she has not yet developed T2DM, being above the relevant threshold. During 
pregnancy, a third factor, insulin resistance, is added to genetic predisposition and suboptimal lifestyle. As 
a consequence, she develops GDM, since the pancreas, although producing larger amounts of insulin, does 
not have adequate functional reserves to completely overcome insulin resistance. Immediately after 
delivery, the placenta is removed and insulin production and action return to the pre-pregnancy level (17). 
 
 
                 Figure 1: The relation of GDM and DM, adapted by Poulakos et al., 2015 (17) 
 
3.1.3 History 
 Gestational diabetes mellitus has been an interesting topic since as early as 1882, that J. Matthews 
Duncan has observed that diabetes may appear during pregnancy, but will eventually disappear after 
delivery (18). In the 1950s, W.P.U Jackson noticed a high likelihood of previous stillbirth and fetal 
macrosomia in women with diabetes and in 1957 Elsie Reed Carrington et al. used the term ‘gestational 
diabetes’ (18). 
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3.1.4 Risk factors 
 GDM carries significant risks for both mother and fetus, being a serious public health issue, so it is 
important to understand the risk factors paying a special attention to the modifiable ones, that contribute to 
its development. By modifying these risk factors the intrauterine environment will be improved, which in 
turn may lower the risk of GDM- related adverse health outcomes for both women and off spring. Well -
documented risk factors include advanced maternal age, family history of  DM, previous pregnancy 
complicated with GDM, non-Caucasian race, increased body weight and cigarette smoking (19, 20).  
 In addition, lifestyle intervention before and during pregnancy seem to affect the risk of GDM. 
Conventionally, promoting physical activity during pregnancy was controversial, as the heat produced 
during exercise was considered as a possible fetal teratogen (21). However, data from at least seven 
observational epidemiological studies provided evidence that increased physical activity before and/or 
during pregnancy were related to a lower risk of GDM (21). In a systematic review and meta-analysis of 
five studies, including 361 GDM cases, recreational physical activity in early pregnancy was related to a 
>20% reduction in the risk of GDM (22). Similarly, in a meta-analysis of seven studies, including 34,929 
women, pre-pregnancy physical activity was on average related to a reduction in GDM risk by >50% (22). 
Among women who did not engage in vigorous activities, a brisk walking pace and stair climbing also were 
associated with a lower risk (23). 
 Dietary factors are also of vital importance as far as the risk of GDM is considered. Potential 
harmful diet patterns include the western type, characterized by  high consumption of fried food, red meat, 
refined grain products, nutrients and beverages with high sugar content (24,25). On the other hand, potential 
beneficial factors include a diet rich in fresh fruits and vegetables, fish, poultry, nuts and fiber content, 
constituting the Mediterranean pattern (24, 26, 27). There is evidence that the latter could lower the risk of 
GDM (28) . 
 Some micronutrients seem also to contribute in GDM development and progress. One of them, is 
vitamin D, which has been thoroughly studied. Current evidence suggests that maternal vitamin D 
insufficiency is associated with a  greater risk of GDM (29). In a systematic review that studied the trials 
conducted in the sunny Mediterranean region concluded that despite high levels of sunshine, maternal 
hypovitaminosis D during pregnancy is prevalent in this region (30). Findings from the investigation of joint 
effects of diet and physical activity, cigarette smoking and BMI indicated that more than 45% of GDM cases 
might have been prevented if women adopted an overall healthy diet and lifestyle and maintained a healthy 
body weight before pregnancy (31) .Even moderate changes in pre-pregnancy weight can affect the risk of 
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GDM among obese women. This may offer further motivation for interventions aimed at reducing obesity 
among women of reproductive age (32). 
 
3.1.5 Complications for mother and fetus 
 Women with GDM are more susceptible to some pregnancy complications such as pre-eclampsia, 
polyhydramnios and increased risk of caesarian section (33). What is of outmost importance, is the increased 
risk of T2DM later in life (34,35). The complications for the fetus and neonate are also deleterious. 
Macrosomia, preterm delivery, risk of caesarian section delivery, stillbirth, shoulder dystocia, neonatal 
hypoglycemia, hyperbilirubinemia and hypocalcemia, polycythemia and respiratory distress syndrome are 
the most frequent and  serious complications  for the fetus, when a pregnancy is complicated  by GDM 
(17,36). 
 
3.1.6 Diagnosis and screening 
 GDM carries risks for the mother and the neonate, but not all adverse outcomes are of equal clinical 
importance. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, a large-scale (25,000 
pregnant women) multinational cohort study, demonstrated that the risk of adverse maternal, fetal, and 
neonatal outcomes continuously increased as a result of maternal glycemia at 24–28 weeks, even within 
ranges previously considered normal for pregnancy (37). These findings have led to reconsideration of the 
diagnostic criteria for GDM. Thus, GDM diagnosis can be accomplished with either of two strategies: 
1. “One-step” 75-g OGTT or 
2. “Two-step” approach with a 50-g (non-fasting) screen followed by a 100-g OGTT for those who screen 
positive. 
          The following table can clarify the two diagnostic procedures and  criteria (38) : 
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Table 1. Diagnostic procedures and criteria for GDM 
One-step strategy:  
Perform a 75-g-OGTT, with plasma glucose measurement when the patient is fasting and at one and two 
hours, at 24-28 week of gestation in women not previously diagnosed with overt diabetes. The OGTT 
should be performed in the morning after an overnight fast of at least 8 hours. The diagnosis of GDM is 
made when any of the following plasma glucose values are met or exceeded:  
-Fasting: 92mg/dL (5.1 mmol/L) 
-1 hour: 180mg/dL (10.0 mmol/L) 
-2 hour: 153mg/dL (8.5 mmol/L) 
Two-step strategy:  
Step 1: Perform a 50-g- GLT (glucose tolerance test), with plasma glucose measurement at one hour, at 
24-28 week of gestation in women with not previously diagnosed with overt diabetes. If the plasma 
glucose level measured 1hour after the load is 140mg/dL (7.8mmol/L) proceed to 100-g-OGTT. 
Step 2: The 100-g-OGTT should be performed when the patient is fasting. The diagnosis of GDM is 
made if at least two of the following four plasma glucose levels (measured fasting and one hour, two 
hours, three hours during OGTT) are met or exceeded: 
 
                           Carpenter and Coustan (39)              NDDG (National Diabetes Data Group) (40)                   
Fasting                95mg/dL (5.3mmol/L)                          105mg/dL(5.8mmol/L) 
1hour                  180mg/dL(10.0mmol/L)                       190mg/dL(10.6mmolL) 
2hours                155mg/dL(8.6mmol/L)                         165mg/dL(9.2mmol/L) 
3hours                140mg/dL(7.8mmol/L)                         145mg/dL(8.0mmol/L) 
 
 
           A cost-benefit estimation comparing the two strategies concluded that the one -step approach is cost-
effective only if patients with GDM receive post-delivery counseling and care to prevent T2DM (41). 
 As the IADPSG (International Association of the Diabetes and Pregnancy Study Groups) criteria 
(“one-step strategy”) have been adopted internationally, further evidence has emerged to support improved 
pregnancy outcomes with cost savings (42) and was  the preferred approach until recently.  
  There are certain factors that place women at a lower risk for the development of glucose 
intolerance during pregnancy, and it is likely not cost-effective to screen such patients. Pregnant women 
who fulfill all of these criteria need not to be screened for GDM according to these recommendations.  
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             This low-risk group comprises women who:  
● are <25 years of age 
● are a normal body weight 
● have no family history (i.e., first-degree relative) of DM 
● have no history of abnormal glucose metabolism 
● have no history of poor obstetric outcome 
● are not members of an ethnic/racial group with a high prevalence of diabetes (e.g., Hispanic American, 
Native American, Asian American, African American, Pacific Islander) 
            Risk assessment for GDM should be considered at the first prenatal visit. Women with clinical 
characteristics consistent with a high risk of GDM (marked obesity, personal history of GDM, glycosuria, 
or a strong family history of DM) should undergo glucose testing as soon as possible. If they are found not 
to have GDM at the initial screening, they should be retested between 24 and 28 weeks of gestation. Women 
of average risk should have testing undertaken at 24 –28 weeks of gestation (38). Obese women should be 
treated and monitored closely, as both GDM and obesity independently contribute to adverse pregnancy 
outcomes and women who are obese and have GDM are clearly at highest risk (43). 
       However, the Endocrine society suggests universal screening (44). More specifically, it is suggested 
that a fasting plasma glucose, HbA1C, or an untimed random plasma glucose should be tested at the first 
prenatal visit (before 13 weeks gestation or as soon as possible thereafter) for those women not known to 
already have diabetes. In the case of overt diabetes, but not gestational diabetes, a second test (either a 
fasting plasma glucose, untimed random plasma glucose, HbA1C, or OGTT) must be performed in the 
absence of symptoms of hyperglycemia and found to be abnormal on another day to confirm the diagnosis. 
The Endocrine society criteria are summarized at the following table: 
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Table 2: Diagnostic criteria for overt diabetes and GDM at the first prenatal visit (before 13 weeks 
gestation or as soon as possible thereafter) for those women not known to already have diabetes. 
Diagnosis  
Fasting 
Plasma 
Glucose, mg/dL 
(mmol/L)  
Untimed (Random) Plasma 
Glucose, mg/dL (mmol/L) 1 
HbA1C, 
%  
Overt diabetes (type 1, 
type 2, or other)  ≥126 (≥7.0)  ≥200 (≥11.1)  ≥6.5%  
Gestational diabetes  92–125 (5.1–6.9)  NA NA 
Abbreviation: NA, not applicable. 
1: Testing should use plasma glucose analyzed at a laboratory, not capillary blood glucose analyzed with a 
blood glucose meter. 
 
3.1.7 Prevalence 
 Late pregnancy is characterized by a two-third decrease in insulin sensitivity, thus in most cases the 
first recognition of women with glucose intolerance occurs during pregnancy (45).  Reported frequencies of 
GDM vary widely among the world. When rates of GDM were calculated in individual HAPO collaborating 
centers using IADPSG criteria, rates differed substantially, range 9–26% (46). HAPO Study participants 
represent consenting research study volunteers and frequencies of GDM that were found in specific centers 
may not be representative of national or regional population-based data (41). In the USA, the percentage of 
women affected by GDM reaches 10%, but in some countries such as India or China the prevalence is almost 
20% (45-49). In European women GDM develops in 2%- 6% of pregnancies. In 90% of these women 
nutritional counseling is sufficient but, in the remainder, pharmacologic therapy is required (50). In the 
USA, there is an increasing trend in GDM, rising from 1.9% during the years 1989-1990 to 4.2% in 2003-
2004 (51,52).  
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3.1.8 Risk of recurrence 
 There is evidence that the hyperglycemic intra-uterine environment has an enduring effect on the 
off-spring, adding to the genetic background the risk of developing obesity, cardiovascular and other 
metabolic diseases, constituting a serious public health issue. The off-spring is in greater risk to become 
obese, and by the time of child-bearing age the probability of developing GDM is considerably greater (53). 
It appears that an elevated fasting serum glucose that is revealed during pregnancy, is a marker of underlying 
metabolic abnormalities that may have preceded pregnancy (54) and may predict a higher likelihood of 
T2DM later in life (55).  
 There are a number of studies that examine the recurrence of GDM in future pregnancies. Gaudier 
et al. found a 52% increased risk of recurrence of GDM in subsequent pregnancies (56). In another study, 
Moses noticed a 35% recurrence rate after following-up 100 women (57). A cohort study in California was 
performed during 1991 to 2008, including 540.956 women. The rate of GDM in second and third 
pregnancies in women without a history of GDM was noted to be 42 and 47 per 1000 births, respectively 
(58).  As compared with women without previous GDM in their first pregnancies, women with a first 
pregnancy complicated by GDM were at significantly increased risk (OR, 13.2; 95% CI, 12.0–14.6) of 
developing GDM during their second pregnancy. As compared with women without GDM in their first and 
second pregnancies, women with pregnancies complicated by GDM during their first but not second 
pregnancies were found to be at 6.3-fold (95% CI, 4.5–9.0) increased risk for developing GDM during their 
third pregnancy. This risk was even more pronounced in the third pregnancy for women who developed 
GDM during their first and second pregnancies (OR: 25.9; 95% CI, 17.4–38.4). In this retrospective cohort 
study with a large number of participants it was shown that the risk of GDM is significantly increased in the 
third pregnancy if the first pregnancy was not complicated by GDM and the second pregnancy was with 
GDM, as compared to if the first pregnancy was with GDM and the second without. It was also noticed that 
the risk of recurrence was higher if both pregnancies were complicated by GDM (58).  
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3.2Vitamin B12 
3.2.1 Vitamin B12 structure 
           Vitamin B12 or cobalamin is a water-soluble vitamin that is implicated in various metabolic 
procedures, hence is interesting to study its function. B12 consists of a central cobalt atom surrounded by a 
heme-like planar corrin ring structure, with the four pyrrole nitrogens coordinated to the cobalt (59). 
Naturally it occurs in the form of 50-deoxyadenosylcobalamin (coenzyme B12) and methylcobalamin 
(MeCbl) (60). The structure of B12 is shown at the following figure:  
 
 
                        Figure 2: The structure of vitamin B12 (59) 
 
3.2.2 Absorption-transport-bioavailability 
 
 The bioavailability of vitamin B12 in foods, depends on its amount in the diet, but in general terms 
is around 50% (61). Nutrient bioavailability broadly refers to the proportion of a nutrient that is absorbed 
from the diet and used for normal body functions. In food, vitamin B12 is bound to protein (such as albumin) 
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and is released in stomach by the action of pepsin in the acid environment, during a process named 
‘proteolysis’. The released B12 binds initially to R-binders which are dietary proteins that have affinity for 
B12. The stomach epithelium contains the parietal cells that secrete gastric acid (by the ATPase) and a 
glycoprotein of 50 kDa called ‘intrinsic factor’ (IF) that binds to vitamin B12. As the vitamin B12-R binder 
complexes pass through the small intestine, the R-binders are hydrolyzed by pancreatic proteases and the 
free vitamin B12 binds to IF. Following a meal, sufficient IF is secreted, in order to bind 2-4 μg of B12. The 
vitamin is absorbed at the distal ileum via receptor mediated endocytosis. The IF-receptor (cubulin) 
recognizes the IF-vitamin B12 complex, it is internalized by an endocytosis- mediated procedure (62). The 
endosomes then fuse with lysosomes; the IF is degraded and the vitamin B12 is released in the cytosol. 
Vitamin B12 is released from the gut epithelial cells as a complex bound to a 38 kDa protein called 
‘transcobalamin II’ (TC-II). This absorption process has a duration about 3-4 hours (63). Vitamin B12 can 
be also absorbed by a diffusion-like process, but it is not very efficient as less than 1% of the provided B12 
is absorbed. This process however, could be important for individuals who lack IF or malabsorb vitamin 
B12 from food. The TC-II complex carries absorbed vitamin B12 to the tissues. The half-life of this complex 
is about 6 minutes.  The main organ that stores vitamin B12 is the liver, in a quantity of 2-3mg in the form 
of 5-deoxyadenosylcobalamin attached to methylmalonylCoA mutase, whereas in plasma the major form 
of B12 is methylcobalamin. The excretion of vitamin B12 is via the bile and urine. The enterohepatic 
circulation results in the effective reuptake. The turnover rate is estimated at about 0,1% per day (64).  
 
3.2.3 Recommended dietary intake-prevalence of B12 deficiency 
             The amount of B12 that is stored in the liver may be sufficient without repletion for 3-5 years. The 
efficient enterohepatic turnover ensures minimal losses of B12. Generally, more than 2.4μg/day are 
considered as adequate intake. As the liver stores of B12 are depleted, TC-II concentrations start to fall 
before any decline of the total serum vitamin B12 level is observed. Therefore, TC-II levels are considered 
more sensitive for detecting B12 insufficiency (65). Moreover, biomarkers of B12 insufficiency are elevated 
serum concentrations of methylmalonic acid (MMA) and homocysteine. Elevated homocysteine is a non-
specific biomarker of B12 insufficiency since it is influenced by folate concentration as well. On the other 
hand, plasma MMA is specific for B12 status (66). 
          The prevalence of vitamin B12 deficiency in UK and the USA is 6% and 20% in population ≤60 years 
and ≥60 years respectively (67). Β12 deficiency is far more prevalent in Asia, and Africa. In India for 
instance, 80% of pre-school children and 70% of adults are vitamin B12 deficient (67). 
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3.2.4 Biochemical function 
          Vitamin B12 has a crucial role in the methylation of DNA, and cell metabolism, as activated 
coenzyme B12 acts as methyl donor for the methylation processes of DNA and RNA. Vitamin B12 
deficiency signifies that there would be a disruption of DNA synthesis and cell cycle, homocysteine levels 
increase, and cell division and differentiation would be negatively affected (68). Vitamin B12 exerts its 
physiological effects through mediating two principal enzymatic pathways: the methylation process of 
homocysteine to methionine and the conversion of methyl malonyl coenzyme A (CoA) to succinyl-CoA. 
Vitamin B12 as a co-factor is implicated in the process of methylation of homocysteine to methionine, 
which is later activated into S-adenosyl-methionine that donates its methyl group to methyl acceptors such 
as myelin, neurotransmitters and membrane phospholipids (68). As it was mentioned before, vitamin B12 
deficiency could lead to hyperhomocysteinemia, which can have toxic effects on the neurons and the 
vascular epithelium. Other complications of B12 deficiency are impaired synthesis of neurotransmitters like 
serotonin and dopamine, and defective fatty acid synthesis (69).  
 
3.2.5 Vitamin B12 and diabetes mellitus 
 Several cross-sectional studies (70-72) and case reports (73-75) have studied vitamin B12 status 
among patients with T2DM. In those studies, metformin was associated with B12 deficiency. However, less 
is known about the association of vitamin B12 and the risk of GDM.  
 
3.3 Purpose of the present review 
            Vitamin B12 is a micronutrient that has many important biochemical functions and is implicated in 
many metabolic pathways. It is a vitamin that is studied in a lesser extent as far as its association with 
metabolic diseases is concerned. Therefore, it is very interesting to study its role and the consequences of 
its deficiency in the context of GDM that is a metabolic disease affecting a percentage of pregnant women 
that is increasing. Therefore, the primary aim of this study was to systematically investigate and meta-
analyze the evidence for the association between B12 deficiency and the risk of GDM. We also tried to 
elucidate the contributory role of potential confounders, such as body mass index, homocysteine, folate and 
triglyceride concentrations, in this association.  
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3.4 Materials and methods 
 
3.4.1 Search strategy 
            A comprehensive search was conducted up to November 30th, 2018.  We researched relevant studies 
in PubMed (Medline), Cochrane Central Register of Controlled Trials and Scopus. The following search 
string was used in PubMed: (((((((((((gestational diabetes[MesH]) OR pregnancy diabetes[tiab]) OR 
gestational hyperglycaemia[tiab]) OR gestational hyperglycemia[tiab]) OR hyperglycaemia 
pregnancy[tiab]) OR hyperglycemia pregnancy[tiab])) OR glucose pregnancy[tiab])) AND ((vitamin 
B12[MeSH]) OR hydroxocobalamine[tiab]))).  
            For Scopus the following search string was used: 
( ( ( ( ( ( ( ( ( ( ( gestational  AND diabetes[title/abstract] )  OR  pregnancy  AND diabetes[title/abstract] )  
OR  gestational  AND hyperglycaemia[title/abstract] )  OR  gestational  AND hyperglycemia[title/abstract
] )  OR  hyperglycaemia  AND pregnancy[title/abstract] )  OR  hyperglycemia  AND pregnancy[title/abstr
act] ) )  OR  glucose  AND pregnancy[title/abstract] ) )  AND  ( ( vitamin  AND b12[title/abstract] )  OR  
hydroxocobalamine[title/abstract] ) ) )  
 
3.4.2 Selection of studies 
 Inclusion criteria were: (i) Studies providing data about the vitamin B12 concentrations during 
pregnancy and the development of GDM; (ii) Studies providing extractable data; (iii) Studies providing 
exact number of pregnant women with GDM and vitamin B12 sufficiency and deficiency. Both cohort and 
case-control studies were eligible. Studies were excluded if: (i) They were referring to other vitamins apart 
from B12, not directly linked to GDM; (ii) They were conducted in vitro; (iii) The control group (women 
with non-GDM) was missing; (iv) They were written in non-English language; (v)They included women on 
antidiabetic medication or were diagnosed with DM before pregnancy.  Exclusion criteria and studies 
excluded with reasons are available as supplementary tables 1 and 2.  
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3.4.3 Data extraction 
 The following data were recorded: (i) First author; (ii) Year of publication; (iii) Country in which 
the study was conducted; (iv) Study design (case control/cohort); (v) Duration of the study; (vi) Criteria of 
definition of GDM; (vii) Total number of pregnant women that participated in the study; (viii) Number of 
women with GDM; (ix) Ethnicity; (x) Trimester of pregnancy that the study was conducted. Parameters 
such as the age and BMI of women with and without GDM, as well as vitamin B12, folate, homocysteine 
and triglyceride concentrations were recorded for both groups (GDM and non-GDM women).  
 
3.4.4  Risk of bias and study quality assessment 
            Newcastle-Ottawa scale (NOS) was used for assessing the quality of each study. This system 
evaluates studies based on three criteria: (i) Participant selection; (ii) Comparability of study groups; (iii) 
Assessment of the outcome or exposure. A study can be awarded a maximum of four stars for the 
selection category, a maximum of two stars for the comparability category and a maximum of three stars 
for the outcome/ exposure category. These results are available in Supplementary table 3.  
 
3.4.5  Statistical analysis  
            The following comparisons were made according to the incidence or prevalence of GDM: (i) 
Pregnant women with GDM and vitamin B12 sufficiency; (ii) Pregnant women with GDM and vitamin B12 
deficiency; (iii) Pregnant women with normal glucose homeostasis and vitamin B12 sufficiency; (iv) 
Pregnant women with normal glucose homeostasis and vitamin B12 deficiency. Additionally, vitamin B12 
concentrations in GDM and non-GDM women were compared. Heterogeneity was tested with the Cochrane 
chi-square test and the degree of heterogeneity was quantified by the I2 statistics. An I2 of 30-60% was 
considered as moderate, whereas values >60% were considered as high degree of heterogeneity. 
Associations were reported as odds ratios (OR) with their 95% confidence intervals (CI). A p value of <0.05 
was considered as statistically significant. All analyses were performed with the latest version of STATA 
software. 
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3.5 Results 
3.5.1 Descriptive data 
 Initial screening yielded 122 publications. After removing duplicates, 97 publications were assessed 
for eligibility. Of those, 87 were excluded based on their title and/or abstract information. Ten studies were 
assessed as full texts for eligibility, four of those were excluded due to the following reasons: (i) The study 
was conducted in vitro (n=2); (ii) The study did not provide data on women with GDM (n=1); (iii) The 
study was written in non-English language (n=1). The reasons for exclusion are summarized in the 
supplementary table 2. Six studies were included in the qualitative analysis and two studies were included 
in the quantitative analysis (76-81), two of which (76,77), could be meta-analyzed. The rest four studies 
(78-81) are excluded because no data on the exact number of GDM according to B12 deficiency/sufficiency 
are provided. A flow diagram of the systematic review is presented below:  
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Figure 3: Flow chart diagram 
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 All studies were published between 2003 and 2016.  The countries in which they were conducted 
were: UK (n=1), Turkey (n=2), India (n=1), Italy (n=1), Poland (n=1). The studies were of prospective 
(n=2), case-control (n=2) and cross-sectional (n=2) design. The number of participants in the studies ranged 
from 61 to 785 pregnant women, yielding a total number of 1810, with 309 cases of GDM. The duration of 
studies varied from one semester to three years (data available from 6 studies). The criteria for diagnosis of 
GDM that were mostly used were Carpenter and Coustan (82), but in some studies the WHO 1999 (5) or 
the American Diabetes Association criteria (83) were used. Apart from indigenous pregnant populations, 
cohorts from UK (76) included pregnant women of different origin, with different social and 
cultural/nutritional habits.  
            Cohorts from Turkey (78,79) included the most homogenous native populations. The studies’ 
descriprive characteristics are summarized in the table 3. Table 4 summarizes the laboratory methods that 
were used in order to measure glucose and definition of vitamin B12 deficiency.  
 
Table 3. Study characteristics     
ID Author Year of 
publication 
Country Study 
design 
Study 
duration 
(years) 
GDM  
criteria 
Number 
of 
pregnant 
women 
Number 
of 
women 
with 
GDM 
Ethnicity Trimester 
of 
pregnancy 
1 Sukumar 2016 UK Case-
control 
3 WHO 1999 344 143 
(41.6%) 
European: 
86.9% 
S.Asian: 
9.3%  
Afro-
Caribbean: 
1.2% 
Other: 1.2% 
3rd 
2 Krishnaveni 2009 India Prospective 2 Carpenter 
and 
Coustan 
785 49 
(6.2%) 
Hindu: 
59.5% 
Muslim: 
33.1% 
Other: 3.8 
3rd 
3 Tarim 2004 Turkey Prospective 1 Carpenter 
and 
Coustan 
304 28 
(9.2%) 
Turkish 3rd 
4 Guven  2006 Turkey Cross-
sectional 
2 Carpenter 
and 
Coustan 
223 30 
(13.4%) 
Turkish 3rd 
5 Seghieri 2003 Italy Cross-
sectional 
one 
semester 
American 
Diabetes 
Association 
93 15 
(16.1%) 
Italian  3rd 
6 Idzior-
Walus 
2008 Poland Case-
control 
No data WHO 1999 61 44 
(72.1%) 
No data 3rd 
 
Institutional Repository - Library & Information Centre - University of Thessaly
04/06/2020 22:55:09 EEST - 137.108.70.13
24 
 
Table 4. Vitamin B12 assay characteristics and status definition  
ID First author Year Method of blood 
glucose assessment 
Method of serum vitamin B12 
assessment 
Vitamin B12 status definition 
(pmol/L) 
 
 
  
   Definition           Range 
1 Sukumar 2010-
2013 
Hexokinase 
enzymatic method 
Electrochemiluminescent 
immunoassay 
<150pmol/L 150-
489pmol/L 
  
2 Krishnaveni 1997-
1998 
Microbiological 
assays 
Microbiological assays <150pmol/L Not 
defined 
  
3 Tarim 2002-
2003 
Glucose oxidase 
method  
Electrochemiluminescence 
technique 
Not defined Not 
defined 
  
4 Guven  2002-
2004 
Glucose oxidase 
method 
Automatic chemiluminescent 
method  
Not defined Not 
defined 
  
5 Seghieri 2001 Glucose GOD-PAP Chemiluminescent Immunoassay Not defined  Not 
defined 
  
6 Idzior-Waluś 2008 Immunoradiometric 
method 
Chemiluminescent immunoassay Not defined Not 
defined 
  
 
Abbreviations: GOD-PAP: glucose oxidase-phenol and 4 aminophenazone 
 
 
 
 
 
 
3.5.2 Comparison of GDM with non-GDM women based on the age and BMI 
Very useful information is provided the following table (Table 5), analyzing the characteristics of the 
pregnant women that participated in the studies. The age and Body Mass Index (BMI) of women with 
normal glucose tolerance and those of women with gestational diabetes mellitus is compared. 
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Table 5: Characteristics of the participants according to age and body mass index (BMI) 
  ID First author Mean age of the e 
of the 
entire 
cohort 
(years) 
Mean age  
of GDM  
women 
(years) 
Mean age 
of non- 
GDM  
women 
(year) 
P-value1 Mean BMI 
of the  
entire  
cohort 
(kg/m2) 
Mean BMI  
of GDM 
women 
(kg/m2) 
Mean BMI 
of non-GDM 
women 
(kg/m2) 
P-value2 
1 Sukumar 30.3 ±5.88 31.4 ±5.8 29.6 ±5.9 P=0.0053 28.8 ±7.46 31.7 ±7.0 26.7 ±7.1 P<0.0001 
2 Krishnaveni 23 N/A N/A - 23.1 N/A N/A - 
3 Tarim N/A 32 ±4.03 26.83 ±4.44 P<0.0001 N/A 27.12 ±2.1 25.24 ±1.99 P<0.0001 
4 Guven N/A 30.0 ±4.3 28.6 ±3.4 P=0.0446 N/A 29.17 ±4.11 27.88 ±2.80 P=0.0297 
5 Seghieri N/A 34.6 ±3.1 32.3 ±3.7 P=0.0264 N/A 26.7 ±3.2 26.3 ±3.7 P=0.6966 
6 Idzior-Walus N/A 30.5 ±6.6 26.2 ±4 P=0.0150 N/A 27.8 ±5.2 25.6 ±3.4 P=0.1123 
 
Data are presented as mean ± SD. Abbreviations: BMI: Body Mass Index; GDM: Gestational Diabetes 
Mellitus; N/A: Not Available  
P-value1: comparison of the age between the groups of GDM and non-GDM women 
P-value2: comparison of the BMI between the groups of GDM and non-GDM women  
 
         All but one (Krishnaveni et al.) studies, provided information about the and BMI of the included. As 
expected, women with GDM, tended to be older and with higher BMI when compared with women with 
normal glucose homeostasis.  
 
 
 
 
 
 
3.5.3 Comparison of vitamin B12 concentrations between women with GDM and 
women with and without GDM 
 
        We obtained data from the six studies with regard vitamin B12 concentrations in both groups of 
pregnant women (GDM and non-GDM) (Table 6 and Table 7).  
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Table 6. Association between maternal vitamin B12 concentrations and GDM 
ID First author Vit.B12 deficiency  GDM/vit. B12 
deficiency 
                                    
GDM/ vit. B12 sufficiency 
              
        YES NO 
1 Sukumar 90(26.2%) 254(73.8) 46(51.1%) 97(38.2%) 
2 Krishnaveni 334 
(43.2%) 
439 (56.7) 29(8.7%) 20 (4.6%) 
3 Tarim N/A N/A N/A N/A 
4 Guven N/A N/A N/A N/A 
5 Seghieri N/A N/A N/A N/A 
6 Idzior-Walus N/A N/A N/A N/A 
 
Data are presented as mean ± SD or median  
Abbreviations: Vit.: Vitamin; N/A: Not Available  
 
Table 7. Comparison of B12 concentrations between GDM and non-GDM women 
ID First author Vitamin B12 concentrations (pg/mL) P value1 
Normal glucose 
tolerance 
GDM 
1 Sukumar 195.6(157.9-
244.6) 
169 (140.2-217.7) P<0.01 
2 Krishnaveni N/A N/A N/A 
3 Tarim 161.8±55.3 150.8±45.5 P=0.1066 
4 Guven 234.5± 295.9 160.4±31.1 P=0.0008 
5 Seghieri 229.93±44.32 242.97±39.24 P=0.2513 
6 Idzior-Walus 287±37.5 262± 82.6 P=0.1079 
 
P-value1: comparison of the groups GDM and non-GDM women for B12 concentrations 
Data are presented as mean ± SD or median  
Abbreviations: N/A: Not Available 
 
        Apart from one study by Krishnaveni et al. (77), the rest five studies provided data on vitamin B12 
concentrations for both GDM and non-GDM groups. Women with GDM had lower levels of vitamin B12 
when compared with non-GDM women. Moreover, a significantly higher proportion of women with GDM 
had B12 insufficiency compared with non-GDM in all the eligible studies.  
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3.5.4 Comparison between folate, homocysteine, and triglyceride concentrations 
between GDM and non-GDM women 
 
         Table 8 presents data on folate, homocysteine and triglyceride concentrations, for both groups of 
pregnant women, GDM and non-GDM. 
 
Table 8. Folate, Homocysteine and Triglyceride concentrations in GDM and non-GDM women 
ID First author  Folate  
non-GDM  
women 
(nmol/L) 
Folate  
GDM women 
(nmol/L) 
Homocycteine  
 non-GDM 
 women 
(μmol/L) 
Homocycteine   
 GDM women  
(μmol/L) 
Triglycerides  
non-GDM  
women 
(mg/dL) 
Triglycerides  
GDM 
women  
(mg/dL) 
1 Sukumar 20.8 (14.5-34.4) 21.5 (13.5-34.5) N/A N/A N/A N/A 
2 Krishnaveni N/A N/A N/A N/A N/A N/A 
3 Tarim 25.1±10.9 14.36±5.05 4.80±0.98 5.70±0.9 180.06±40.95 249±43.53 
4 Guven 15.1±7.25 14.36±5.05 7.4±1.6 9.0±3.1 N/A N/A 
5 Seghieri 31.3±16.5 33.3±17.9 4.45±1.52 5.88±2.26 212.3±70.79 247.7±115.04 
6 Idzior-Walus 25.1±13.3 25.3±13.59 7.4±1.1 8±2 168±44.24 238±79.64 
 
Data are presented as mean ± SD or median  
Abbreviations: N/A: Not Available 
 
         It is observed that the levels of folate are almost the same in GDM and non-GDM women. This fact 
may be attributed to the folate supplements that most women are given by their medical practitioner since 
the very beginning of their pregnancy (76). 
        As far as homocysteine is concerned, we can observe that the levels are increased in the group of 
pregnant women with GDM when compared to the group of women with normal glucose tolerance, as well 
as the triglyceride concentrations.  
        For the homocysteine levels, Tarim et al. observed a p value of p<0,001, Guven et al. a p value of 
p<0,01, Seghieri et al. a p value of p=0,003 and finally Idzior-Walus et al. a statistically non-significant p 
value, when the groups of women with normal glucose tolerance and women with GDM were compared. 
When comparing the results obtained for the triglyceride levels, the study of Tarim et al. observed a p value 
p<0,0001, the study of Idzior-Walus et al. a p value p=0,002 and finally Seghieri et al. a p value that was 
statistically non-significant.  
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3.5.5 Meta-analysis 
      Only two of the six studies included in this systematic review could be meta-analyzed (Sukumar et al, 
Krishnaveni et al.) (76,77). The rest of studies did not provide data on the exact number of pregnant women 
with GDM according to vitamin B12 status.  
       Pregnant women with vitamin B12 deficiency demonstrated an increased risk of developing GDM 
compared with those with vitamin B12 deficiency: OR 1.81 (95% CI 1.25-2.63), with very low 
heterogeneity (Figures 4 and 5). 
 
 
 
 
 
Figure 4:  Meta-analysis results 
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Figure 5:  Statistics results of the meta-analysis 
 
 
 
3.6 Discussion 
GDM is the most common metabolic disorder during pregnancy and is also associated with adverse 
effects on pregnancy, on the vascular system and is also associated with birth defects (84,85). In a systematic 
review and meta-analysis by Eades et al., published in 2017, that included 40 studies conducted in 11 
European countries with a total population of 1.778.399 participants, the mean prevalence of GDM was 
5.4% (95% CI, 3.8-7.8%). The highest prevalence was found in studies conducted in Italy (10%; 95% CI, 
7.6- 13) and the lowest in Sweden (1.5%;95% CI, 1-2.3). Highest prevalence was found in countries in 
Southern Europe (9.6%; 95% CI, 7.3-12.6) and lowest in Northern Europe (2.3%; 95% CI, 1.3- 3.8) (86). 
Another important finding of this meta-analysis was that the prevalence of GDM increased every decade, 
with the lowest in the 1980’s (0.9%, range: 0.1-10) and the highest in the 2010’s (11.1%, range: 5.7-20.6).  
     This increasing prevalence of GDM and the harmful consequences for both the pregnant woman and the 
newborn, make the study of this metabolic disease interesting and the researchers are provoked to elucidate 
the possible pathophysiological mechanisms and the relation of the disease to variable modifiable 
parameters.  
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    Vitamin B12 seems to have a fundamental role in the synthesis of DNA, proteins and lipids. Along with 
folate, they participate in a series of cellular reactions collectively known as one-carbon metabolism, as 
essential cofactors for the synthesis of methionine from homocysteine (87) and at the mitochondrial level, 
vitamin B12 is required as a coenzyme for the conversion of methylmalonyl-CoA to succinyl-CoA, in the 
process of fatty acid oxidation. In the absence of vitamin B12 the process is inhibited and lipogenesis is 
promoted (88).  
    To the best of our knowledge, this is the first systematic review and meta-analysis on the association 
between vitamin B12 deficiency and GDM. Regarding the primary endpoint, we found two studies 
providing available data. It was shown that pregnant women who are vitamin B12 deficient are almost at 
two-fold increased risk of developing GDM. With regard to the prevalence of B12 deficiency, in the first 
study conducted in UK (76), 26.2% of pregnant women were B12 deficient, while in the second study, 
conducted in India (77) where vegetarianism is part of the country’s culture, almost half of the population 
was deficient (43.2%).  
      Regarding the second endpoint, in an attempt to elucidate potential parameters that could explain this 
phenomenon of discrepancy of the percentages of vitamin B12 deficient and non-deficient pregnant women, 
we found differences in folate, homocysteine and triglyceride concentrations as well as in BMI regarding 
B12 deficiency or sufficiency in pregnant women.  
      Folate deficiency is rare during pregnancy due to the folate supplements that women take since the very 
beginning of their pregnancy (91% of the cohort was taking folate supplements in the study by Sukumar et 
al.) (76). In the same study, the serum folate levels did not have a significant difference in the group of 
women with GDM and non-GDM women. However, after adjusting for age, parity, ethnicity, smoking 
status, serum folate showed a positive association with vitamin B12 (β coefficient :0.23; p-value <0.001).  
Folate deficiency in this study was not significantly associated with a risk of GDM. In the study by Seghieri 
et al. (80) that studied folate concentrations during pregnancy, there was not a remarkable difference 
between the concentrations in the two groups of pregnant women, folate concentrations for non-GDM and 
GDM group were: 31.3 ± 16.5 and 33.3±17.9 nmol/L respectively. The p-value was not significant.  
As far as homocysteine is concerned, hyperhomocysteinemia, as a marker of both folate and vitamin 
B12 deficiency, has been studied and identified as a risk factor for cardio-vascular diseases and insulin 
resistance-DM (89-91). Four studies included in this systematic review, Tarim et al. (78), Guven et al. (79), 
Seghieri et al. (80), Idzior-Walus et al. (81), reported that homocysteine levels were increased in pregnant 
women with GDM when compared with non-GDM women. This increase is unlikely due to the possible 
differences in oral folate supplementation or in serum albumin, the two possible mechanisms that are 
previously identified as modulators of homocysteine concentration during pregnancy (92). Homocysteine 
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concentrations, can be modified and regulated by several factors, for example genetically determined 
enzyme alterations, nutritionals status, underlying diseases, age, medications and pregnancy. The latter is 
the only one that specifically decreases plasma homocysteine concentrations (92). In general, during 
pregnancy, homocysteine levels are lower than normal, and this is due to either a physiological response to 
the pregnancy, an increase in estrogen concentration, hemodilution from the increased plasma volume of 
the pregnant woman, or by an increased demand for the amino acid methionine from the mother and the 
fetus (93). Three studies, Tarim et al. (78), Guven et al. (79), Seghieri et al. (80), included in our systematic 
review that provided data about homocysteine concentrations in women with GDM and women with normal 
glucose homeostasis, concluded that they are increased in GDM women. However, Idzior-Walus et al. (81) 
did not observe any difference in homocysteine levels in the blood between GDM and non-GDM pregnant 
women. This means that more studies are needed to confirm this information. In the study by Guven et al. 
(79), there was a weak partial correlation, controlled for homocysteine, between serum vitamin B12 and 
folate levels (r=0.22, p=0.01). However, serum homocysteine levels demonstrated a negative partial 
correlation, when controlled for vitamin B12, with serum folate (r= -0.172, p=0.02). Idzior-Walus et al. 
(81), observed that in women with GDM, serum vitamin B12 concentrations correlated negatively with 
homocysteine (r= -0.47, p<0.01). More studies are thus needed, in order to prove the relation between 
vitamin B12, homocysteine and GDM.  
Hypertriglyceridemia is a common feature in insulin-resistant patients (94). Triglycerides may 
increase oxidative stress and impair insulin action (95). Idzior-Walus et al. (81) demonstrated that in women 
with GDM serum vitamin B12 concentrations are correlated negatively with serum triglycerides (r= -0.42, 
p<0.01). Tarim et al. (78), observed that the mean triglycerides and very-low density lipoprotein (VLDL) 
concentrations in the group of GDM women were significantly higher than those of the control group 
(p<0.05). In the study by Seghieri et al. (80) no difference was found between the two groups. Additionally, 
in this study it is interesting to point-out that vitamin B12 correlated not only with total homocysteine, but 
also with serum triglyceride concentrations.  
With respect to BMI, the results were not conclusive when pregnant women with GDM were 
compared with non-GDM women. Three of the studies included in this systematic review, by Sukumar et 
al. (76), Krishnaveni et al. (77) and Tarim et al. (78), concluded that the BMI of pregnant women with GDM 
was higher when compared with non-GDM women. Interestingly, Sukumar et al. (76) observed that women 
with vitamin B12 deficiency had higher BMI in the first trimester than those who were vitamin B12 
sufficient (30.9 ± 7.56 vs. 28.0 ± 7.30 kg/m2, p < 0.05). After adjusting for age, parity, ethnicity, smoking 
status, and gestation of blood tests, BMI was a significant negative predictor of B12 (β coefficient −0.21; 
95% CI: −0.47, −0.13; p = 0.001). It is also impressive the fact that third trimester vitamin B12 insufficiency 
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was associated with 2.4 times higher risk of obesity in the first trimester. Krishnaveni et al. (77) 
demonstrated that vitamin B12 concentrations were adversely associated with BMI and sum of skinfolds.  
In the same context as Sukumar et al. (76), he observed that vitamin B12 deficiency was associated with 
higher BMI, larger sum of skinfolds, higher insulin resistance and increased risk of GDM. Tarim et al. (78), 
also showed that the BMI of pregnant women with GDM was higher than in the control group (p<0.05). 
The rest of the three studies in this systematic review by Guven et al. (79), Seghieri et al. (80) and Idzior-
Walus et al. (81) did not prove any significant difference in BMI of GDM and non-GDM women.  
          The first study showing that women with vitamin B12 deficiency are at higher risk to develop GDM, 
was conducted by Krishaveni et al. (77) in India during the years 1997-1998 and published in 2009. GDM 
was 2.14 times more frequent (95% CI: 1.11-4.13) in vitamin B12 deficient compared with non-deficient 
pregnant women. The former group was also more likely to be in the highest quartile of adiposity (OR for 
BMI: 2.1, p<0.001; OR for the sum of skinfolds:1.7 p=0.004). In this study, both adiposity and the incidence 
of GDM increased as the folate concentrations increased in women with vitamin B12 deficiency. On the 
other hand, in women with normal vitamin B12 concentrations, insulin resistance decreased as the folate 
concentrations increased. However, the interaction between B12 deficiency and folate concentrations was 
not significant. In this study, a high prevalence of B12 deficiency was noticed (≥40%) and this was in part 
explained by the Indian culture and the vegetarianism as a way of lifestyle. Hindu women, who are mainly 
vegetarian had the lowest vitamin B12 concentrations, and whereas Muslim women, who are mainly non-
vegetarian, had the lowest folate concentrations (77). The risk of GDM was higher among pregnant women 
with vitamin B12 deficiency and high folate concentrations. The authors reported for the first time a link 
between vitamin B12 deficiency, adiposity and its related disorders, proposing the term ‘diabesity’.  
         One possible mechanism is that B12 deficiency may promote adiposity. A second possible 
interpretation is that adiposity lowers plasma B12 concentrations. Especially for pregnant women, possible 
mechanisms include greater hemodilution, increased transfer of nutrients to the fetus or increased urinary 
losses due to increased glomerular filtration rate. The interesting fact is that in this study, there was a five-
year follow-up of the pregnant women, and this phenomenon of ‘diabesity’ persisted even after five years 
after pregnancy (77). In the context of adequate or high folate concentrations, there are plausible 
biochemical mechanisms that resonate why vitamin B12 deficiency could cause adiposity (96). When there 
is deficiency of B12, folate is trapped as inactive 5-methyltetrahydrofolate (97). This leads to impaired 
methionine synthesis, thus impaired protein synthesis, that may hinder lean tissue deposition. In addition, 
impaired conversion of methylmalonyl-CoA to succinyl-CoA, for which vitamin B12 acts as a cofactor.  In 
the context of B12 deficiency, there is accumulation of methylmalonyl-CoA, which may increase 
lipogenesis and insulin resistance (96). These results are in accordance with the results of the PMNS (Pune 
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Maternal Nutrition Study) study, also conducted in India (98). It has been suggested that the widespread 
vitamin B12 deficiency in India may predispose Indians to the susceptibility to adiposity and the later to 
DM (‘diabesity’) and that this phenomenon is further exacerbated by increased folate levels.  
         The second study that investigated the connection between maternal vitamin B12 levels during 
pregnancy and the risk of GDM, was published in 2016 by Sukumar et al. (76). Although this study was 
retrospective in design, in contrast with the previous prospective study by Krishnaveni et al. (77), confirmed 
its results in a UK population, for the first time. Not only this study demonstrated that low vitamin B12 
status during pregnancy is associated with a higher risk for GDM, but also it was observed that higher BMI 
during the first semester, was an independent predictor of a B12 deficiency. An interesting remark of this 
study was that low levels of B12, were associated with macrosomia in the group of non-GDM women, and 
this could be partly mediated by maternal BMI (77).  
        The two studies have some differences as far as the BMI of the pregnant women, as a parameter of the 
link between maternal B12 deficiency and GDM, is concerned. In the study by Krishnaveni et al., although 
the magnitude of association of B12 deficiency and risk of GDM was the same as the second study by 
Sukumar et al., the significance was lost when adjusted for maternal BMI. On the other hand, the 
significance persisted when adjusted for maternal BMI in the second study, a fact that may be interpreted 
as a potential independent effect of B12.  
      The recent study by Knight et al. although it was not performed in a GDM population, also supports the 
inverse link between B12 levels and insulin resistance in pregnant Caucasian, white women (99). 
Prospective longitudinal studies are needed to investigate whether the presence of low B12 status in early 
pregnancy independently increases the risk of incident GDM and also to investigate the relation between 
maternal BMI and B12 status.  
       It is interesting to observe that the rates of vitamin B12 deficiency differ between the two studies of our 
meta-analysis. 26.2% in the study of Sukumar et al. (76) and 43.2% in the study by Krishnaveni et al. (77). 
The rates differed when we compared non-GDM populations, 21.9% and 20% respectively (76,99).  It seems 
that vitamin B12 deficiency is not limited in Indian populations that are mainly vegetarian. Interestingly, 
the frying and roasting of meat products reduces the bioavailability of vitamin B12 by 20%–40% (100), so 
higher consumption of processed foods may increase the risk of both B12 deficiency and metabolic diseases. 
As it was mentioned above, a decrease in concentrations of vitamin B12 is common during pregnancy, due 
to a decrease in the fraction bound to the inactive haptocorrin. However, it is not clear yet if there is a 
decrease in the active form, holotranscobalamin (99). Another issue, is that there are not specific cut-off 
points for the B12 concentrations during pregnancy, and we define the deficiency according to the non-
pregnant reference range, with levels <150pmol/l defined as deficiency.  
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       In all of the studies included in this systematic review, the folate deficiency was rare, which was 
reassuring. This may be attributed to folate supplements that are prescribed in women since the very 
beginning of their pregnancy, by their healthcare practitioner. However, the combination of high folate with 
low vitamin B12 seem to have deleterious effects on both the mother and the newborn as it was mentioned 
before.  
      In our meta-analysis, the result was statistically significant (OR: 1.81; 95% CI, 1.25-2.63), a fact that 
confirms our initial hypothesis that vitamin B12 deficiency is associated with a higher risk of GDM. The 
present study has several limitations though. The first, is that a limited number of studies were included. 
Second, the diagnosis of GDM was set with different criteria. Third, not all studies investigated the 
association between the parameters that may affect B12 concentrations, therefore it was impossible to 
perform a meta-regression analysis. 
     More studies are needed in this context, in order to prove the direct causation of vitamin B12 deficiency 
with GDM, and investigate the effects of different BMI on the association between vitamin B12 and GDM, 
as well as the parameter age in the same concept. It will be interesting to design prospective studies in order 
to observe how some components of the metabolic syndrome, such as triglycerides, high-density lipoprotein 
(HDL) and arterial blood pressure may or not affect vitamin B12 concentrations. In addition, specific cut-
off points for vitamin B12 need to be set for pregnancy, in order to avoid using the same reference range as 
in the non-pregnant population and be more accurate. 
       It is also important to mention that there are no guidelines to address how often patients with T1DM or 
T2DM and GDM should be supplemented with vitamin B12. The optimal supplementation dose of the 
vitamin is unknown as well. A study from the USA published in 2012, showed that administration of oral 
vitamin B12 among T2DM patients on long-term use of metformin was ineffective in terms of correcting 
vitamin B12 deficiency. The doses in the multivitamin formulations in this study were inadequate as it 
seems to correct the levels of vitamin B12 (101). There is also evidence that vitamin B complex 
supplementation is effective in lowering plasma homocysteine concentrations, but the mechanism seems to 
be unclear (102). In a multi-center, randomized, double-blind trial involving patients with diabetic 
neuropathy, subjects received a high-dose of vitamin B-complex supplementation or placebo. The results 
were inconclusive, as participants in the therapy group had significantly lower plasma homocysteine 
concentrations, but they also had a rapid decline in renal function and increased rates of vascular events, 
such as stroke and myocardial infarctions (102). Thus, no firm conclusion can be made, regarding the role 
of vitamin B supplementation in DM. This, stresses the need for further studies to determine the optimal 
vitamin B12 supplementation dose and first of all to conclude if the supplementation will be beneficial for 
the patients with DM.  
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       As far as GDM is concerned, the studies about supplementation with vitamin B in general and vitamin 
B12 more specifically, there are scarce. There is a potential benefit from B12 supplementation during 
pregnancy and lactation period, as far as lactation and breast milk status is concerned (103,104). In addition, 
there is a benefit from vitamin B12 supplementation in early pregnancy for the subsequent 
neurodevelopment and growth in the off-spring (105). A study that was performed in a different population, 
the HOPE study (Heart Outcomes Prevention Evaluation) 2, a randomized, double-blind trial which 
evaluated the role of vitamin B therapy (vitamin B9: 2.5 mg, vitamin B6: 50 mg, vitamin B12:1 mg) in 
reducing the risk of major vascular events. The participants were aged 55 or older and had either 
cardiovascular disease (CVD) or DM. The conclusion was that daily vitamin B therapy reduced 
homocysteine concentrations by 25%, but had no beneficial effects on major CVD events except for a 
reduction in the incidence of stroke. (106). Thus, the role of vitamin B supplementation in patients with 
CVD or DM are contradictory. However, further clinical trials with larger sample sizes and longer follow-
up periods are required, in order to determine the possible long-term effects and safety. The dosing of such 
supplements should be investigated as well, before specific vitamin supplements are widely recommended 
in patients with DM. Especially for the sensitive period of pregnancy, extra care should be taken when 
recommending any vitamin supplementation, since data are not robust. The potential harmful effects and 
hazards to the pregnant woman, the fetus or the newborn, that could be provoked by their administration 
should be studied thoroughly and special concern and attention is required from the health care practitioner, 
nurse, or midwife when recommending them.  The recently published report ‘WHO recommendations on 
antenatal care for a positive pregnancy experience’ only recommends iron and folic acid to pregnant women 
(107). Maybe it is time to review these recommendations, and update the international guidelines about 
supplementation before and during pregnancy with vitamin B-complex.  
       
 
3.7 Conclusions 
     In summary, this systematic review and meta-analysis in pregnant women, shows that pregnant women 
with vitamin B12 deficiency are at two-fold risk to develop GDM during pregnancy, when compared with 
those who have sufficient vitamin B12 levels. This should be taken into account when building prognostic 
models for detection of GDM, especially in high risk women. Well-designed prospective, cohort and 
interventional studies will further elucidate this association and will investigate whether supplementation 
with B12 before or during pregnancy could reduce this risk. 
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SUPPLEMENTARY MATERIAL: 
 
Supplementary table 1: Exclusion/Inclusion criteria 
Exclusion criteria:  
a. Not relevant with the subject  
b. Not extractable data 
c. Pregnant women treated already with drugs for GDM 
d. Non-English language 
e. Conducted in animals or in vitro 
Inclusion criteria: 
a. Population of the study includes pregnant women 
b. Data on vitamin B12 concentration for GDM and non-GDM women 
c. Outcome: GDM 
 
 
 
 
Supplementary table 2. Full-text articles excluded from data synthesis. 
Study Year Reasons for exclusion Number 
of studies 
Adaikalakoteswari 
A. et al.  
2017 Study in vitro  2 
Sinclair KD et al.  2007 
Knight BA et al.  2015 No data on women with GDM  1 
Paez Pumar JI. 1959 Non-English language  1 
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Supplementary table 3. Study quality as assessed by the Newcastle-Ottawa scale. 
 
Id First author, Year Selection Comparability Exposure / 
Outcome 
Overall quality 
1. Sukumar, 2016 4 2 2 Good 
2. Krishnaveni, 2009 4 2 2 Good 
3. Tarim, 2004 4 2 2 Good 
4. Guven , 2006 4 2 2 Good 
5. Seghieri, 2003 4 2 2 Good 
6. Idzior-Walus, 2008 4 2 2 Good 
 
 
According to the Newcastle-Ottawa scale, a study can be awarded a maximum of four stars for the selection 
category, a maximum of two stars for the comparability category and a maximum of three stars for the 
outcome/exposure category. 
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